Carol L. Brown

ORCID: 0000-0001-8411-2023
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Endometrial and Cervical Cancer Treatments
  • Ovarian cancer diagnosis and treatment
  • Uterine Myomas and Treatments
  • Cancer Genomics and Diagnostics
  • BRCA gene mutations in cancer
  • Cervical Cancer and HPV Research
  • Endometriosis Research and Treatment
  • Economic and Financial Impacts of Cancer
  • Intraperitoneal and Appendiceal Malignancies
  • Genetic factors in colorectal cancer
  • Minimally Invasive Surgical Techniques
  • Global Cancer Incidence and Screening
  • Ethics in Clinical Research
  • Genomics and Rare Diseases
  • Surgical Simulation and Training
  • Health Systems, Economic Evaluations, Quality of Life
  • Cancer-related molecular mechanisms research
  • Cancer survivorship and care
  • Cancer Risks and Factors
  • Advances in Oncology and Radiotherapy
  • Gynecological conditions and treatments
  • Diversity and Career in Medicine
  • Multiple and Secondary Primary Cancers
  • Infection Control and Ventilation
  • Estrogen and related hormone effects

Memorial Sloan Kettering Cancer Center
2016-2025

Kettering University
2011-2024

Cornell University
2014-2024

University of New Mexico
2012-2015

Health Net
2015

Tulane University
2015

National Cancer Institute
2015

Henry Ford Hospital
2015

Emory University
2015

Kaiser Permanente
2015

<h3>Importance</h3> The link between<i>BRCA</i>mutations and uterine cancer is unclear. Therefore, although risk-reducing salpingo-oophorectomy (RRSO) standard treatment among women with<i>BRCA</i>mutations (<i>BRCA</i>+ women), the role of concomitant hysterectomy controversial. <h3>Objective</h3> To determine risk for distribution specific histologic subtypes in<i>BRCA</i>+ after RRSO without hysterectomy. <h3>Design, Setting, Participants</h3> This multicenter prospective cohort study...

10.1001/jamaoncol.2016.1820 article EN JAMA Oncology 2016-07-01

Importance Although differences in the prevalence of key cancer-specific somatic mutations as a function genetic ancestry among patients with cancer has been well-established, few studies have addressed practical clinical implications these for growing number biomarker-driven treatments. Objective To determine if approval precision oncology therapies benefited from various ancestral backgrounds equally over time. Design, Setting, and Participants A retrospective analysis samples solid...

10.1001/jamaoncol.2024.5794 article EN JAMA Oncology 2025-01-09

The seminal Gynecologic Oncology Group study on surgical pathologic spread patterns of endometrial cancer demonstrated the risk pelvic lymph node metastasis for clinical stage I based tumor grade and thirds myometrial invasion. However, FIGO staging system assigns by categorizing depth invasion in halves. objective this was to determine incidence as per current system. We reviewed records all patients who underwent primary at our institution between May 1993 November 2005. To make cohort...

10.1111/j.1525-1438.2007.00996.x article EN International Journal of Gynecological Cancer 2007-07-20

The American Society of Clinical Oncology (ASCO) has embarked on an intensive campaign to integrate elimination cancer health disparities into the Society's overall mission and activities. Key components this commitment are enhancing awareness disparities; improving access care; supporting research disparities. Major objectives advance education oncology community in care patients from underserved minority populations; increase diversity clinical workforce as a requisite for underserved;...

10.1200/jco.2008.21.1680 article EN Journal of Clinical Oncology 2009-04-30

<h3>Objective</h3> Risk-reducing salpingo-oophorectomy (RRSO) is recommended for women with <i>BRCA</i> mutation due to increased risk of pelvic serous carcinoma. Serous tubal intraepithelial carcinoma (STIC) a pathologic finding unknown clinical significance. This study evaluates the outcome patients isolated STIC. <h3>Materials/Methods</h3> We retrospectively reviewed medical records consecutive germline <i>BRCA1/2</i> or high-risk personal family history ovarian cancer who underwent RRSO...

10.1097/igc.0b013e3182a80ac8 article EN cc-by-nc-nd International Journal of Gynecological Cancer 2013-10-30

Abstract Accurate ancestry inference is critical for identifying genetic contributors of cancer disparities among populations. Although methods to infer have historically relied upon genome-wide markers, the adaptation targeted clinical sequencing panels presents an opportunity incorporate into routine diagnostic workflows. We show that global ancestral contributions and admixture continental populations can be quantitatively inferred using markers captured by MSK-IMPACT panel. In a...

10.1158/2159-8290.cd-22-0312 article EN Cancer Discovery 2022-09-01

Abstract Background: Poorer survival from endometrial cancer in blacks than whites is well documented. The aims of this study were to determine whether diabetes, hypertension, or other conditions influence and accounting for these reduces racial disparity. Methods: Using the SEER-Medicare database, we investigated comorbid on black white women age ≥66 with cancer. We used Cox proportional hazards regression evaluate comorbidities separately differences between after adjustment medical...

10.1158/1055-9965.epi-11-0735 article EN Cancer Epidemiology Biomarkers & Prevention 2012-05-01

To assess the direct costs of three surgical approaches in uterine cancer and cost-effectiveness incorporating robot-assisted surgery.A cost system that allocates actual resources used to treat each patient, as opposed borrowing data from a billing system, was determine for patients who underwent surgery 2009 2010. These included all aspects care up 6 months after discharge. Total amortized capital dual-console robotic platforms with 5 years service contracts. Nonamortized were also...

10.1097/aog.0000000000000223 article EN Obstetrics and Gynecology 2014-04-07

Abstract Although the incidence of endometrial carcinoma (EC) is similar in Black and White women, racial disparities are stark, with highest mortality rates observed among patients. Here, analysis 1,882 prospectively sequenced ECs using a clinical FDA-authorized tumor–normal panel revealed significantly higher prevalence high-risk histologic molecular EC subtypes self-identified (n = 259) compared 1,623) Clinically actionable alterations, including high tumor mutational...

10.1158/2159-8290.cd-23-0546 article EN Cancer Discovery 2023-08-31
Coming Soon ...